"The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Bexsero is the second vaccine approved"...
Information For Vaccine Recipients Or Parents/Guardians
Before administration, healthcare providers should inform patients, parents or guardians of the benefits and risks of immunization with Typhim Vi vaccine.
Prior to administration of Typhim Vi vaccine, healthcare providers should ask patients, parents and guardians about the recent health status of the patient to be immunized.
Travelers should take all necessary precautions to avoid contact with or ingestion of contaminated food and water.
One dose of vaccine should be given at least 2 weeks prior to expected exposure.
Reimmunization consisting of a single-dose for US travelers every two years under conditions of repeated or continued exposure to the S. typhi organism is recommended at this time.14
As part of the child's or adult's immunization record, the date, lot number, and manufacturer of the vaccine administered should be recorded.17
14 Recommendations of the Immunization Practices Advisory Committee (ACIP). Typhoid Immunization. MMWR 43: No. RR-14, 1994
17 CDC. Vaccine Adverse Event Reporting System - United States. MMWR 39: 730-733, 1990
Last reviewed on RxList: 10/10/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Typhim Information
Report Problems to the Food and Drug Administration
Find out what women really need.